AI assistant
Elekta — Regulatory Filings 2021
Jan 22, 2021
2906_rns_2021-01-22_93470e6a-34b5-4cc0-be90-6ffc6888ac0e.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
Elekta divests its stake in ViewRay
STOCKHOLM – Elekta AB (EKTA-B.ST) announced today that it has sold its 7.3 percent of the outstanding common stock (11,501,597 shares) in ViewRay, Inc. (Nasdaq:VRAY). Elekta has no remaining shares in ViewRay after the transaction.
The shares in ViewRay were purchased in a public offering in December 2019 at USD 3.13 per share and sold today at USD 4.65 per share. The proceeds from the sale were approximately USD 53 million, resulting in a gain of approximately USD 17.5 million. The gain will be booked in Elekta's third quarter 2020/21.
#
For further information, please contact:
Mattias Thorsson, VP Corporate Communications Tel: +46 70 865 8012, e-mail: [email protected] Time zone: CET: Central European Time
Cecilia Ketels, Head of Investor Relations Tel: +46 76 611 76 25, e-mail: [email protected] Time zone: CET: Central European Time
This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 07:30 CET on January 22, 2021. (REGMAR)
About Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.